Novavax Achieves First $50 Million Milestone in Sanofi Partnership, Advancing COVID-19 and Influenza Vaccine Development

Novavax and Sanofi Partnership Milestone

Novavax, Inc. has announced a significant achievement in its partnership with Sanofi, marking a pivotal moment in their collaborative efforts to combat infectious diseases. The company has successfully reached the first milestone associated with its Phase 2/3 clinical trial for the COVID-19 vaccine in children, resulting in a $50 million milestone payment from Sanofi. This achievement not only highlights the progress in their collaborative agreement but also strengthens Novavax's financial position.

Advancing Vaccine Development

The partnership between Novavax and Sanofi extends beyond the standalone COVID-19 vaccine. It includes the development of two combination vaccine candidates that aim to prevent both influenza and COVID-19. These candidates have recently been granted Fast Track designation by the U.S. FDA and have progressed to Phase 1/2 clinical trials. This advancement represents a significant step forward in the fight against these infectious diseases, with the potential for future milestone payments and royalties for Novavax.

Financial and Strategic Implications

Following the initial upfront payment at the signing of the agreement in May 2024, this $50 million milestone is the first of many potential financial benefits for Novavax. The agreement outlines additional milestones of up to $300 million related to the COVID-19 vaccine and up to $350 million for combination products developed by Sanofi. Moreover, Novavax is eligible to receive up to $200 million for the first four products created by Sanofi utilizing its Matrix-M adjuvant, with the potential for additional milestone payments and ongoing royalties.

Corporate Growth Strategy

Novavax's corporate growth strategy is centered around pursuing additional partnerships for its late-stage and early-stage Research and Development assets, including its Matrix-M adjuvant. This strategy aims to position the company for ongoing value creation through similar contractual frameworks. The achievement of this milestone with Sanofi is a testament to the effectiveness of this strategy and Novavax's commitment to advancing vaccine technology.

About Novavax

Novavax, Inc. is a global company dedicated to improving health through the discovery, development, and commercialization of innovative vaccines. Based in Gaithersburg, Md., Novavax utilizes a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology, and its patented Matrix-M adjuvant to enhance immune responses. The company's portfolio includes its COVID-19 vaccine and a pipeline of vaccine candidates, including a COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.

Forward-Looking Statements

Novavax cautions that statements regarding the future of the company, its operating plans, prospects, and the potential achievement of additional milestones or receipt of royalties are forward-looking and subject to numerous risks and uncertainties. These include challenges related to manufacturing, regulatory authorization, clinical trials, and partnership opportunities. Investors are encouraged to consider these risks and uncertainties carefully.

For more information, visit novavax.com and follow Novavax on LinkedIn.